Cited by 566Amyotrophic Lateral Sclerosis ResearchGenetic Neurodegenerative DiseasesHereditary Neurological Disorders

Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons

Open access
Shi, Yingxiao, Lin, Shaoyu, Staats, Kim A, Li, Yichen, Chang, Wen-Hsuan, Hung, Shu-Ting, Hendricks, Eric, Linares, Gabriel R +35 more·2018·Nature Medicine

Abstract

An intronic GGGGCC repeat expansion in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but the pathogenic mechanism of this repeat remains unclear. Using human induced motor neurons (iMNs), we found that repeat-expanded C9ORF72 was haploinsufficient in ALS. We found that C9ORF72 interacted with endosomes and was required for normal vesicle trafficking and lysosomal biogenesis in motor neurons. Repeat expansion reduced C9ORF72 expression, triggering neurodegeneration through two mechanisms: accumulation of glutamate receptors, leading to excitotoxicity, and impaired clearance of neurotoxic dipeptide repeat proteins derived from the repeat expansion. Thus, cooperativity between gain- and loss-of-function mechanisms led to neurodegeneration. Restoring C9ORF72 levels or augmenting its function with constitutively active RAB5 or chemical modulators of RAB5 effectors rescued patient neuron survival and ameliorated neurodegenerative processes in both gain- and loss-of-function C9ORF72 mouse models. Thus, modulating vesicle trafficking was able to rescue neurodegeneration caused by the C9ORF72 repeat expansion. Coupled with rare mutations in ALS2, FIG4, CHMP2B, OPTN and SQSTM1, our results reveal mechanistic convergence on vesicle trafficking in ALS and FTD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4490

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PIKFYVE inhibition improves proteostasis in neurons.

    “improves proteostasis in neurons (Shi et al., 2018; Staats et al., 2019).”

    From ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids (2021) · cites this paper as Shi et al., 2018

    In “Small molecule and genetic regulators of endosomal trafficking rescue patient iMN survival” (page unavailable), the paper reports that PIKFYVE inhibition lowers glutamate-receptor levels and improves survival in C9ORF72 patient motor neurons. It proposes that increased autophagosome–lysosome fusion may help remove dipeptide repeat proteins, but does not establish a general improvement in neuronal proteostasis. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • PIKFYVE inhibition increases the number of EEA1-positive endosomes and LAMP1-positive lysosomes.

    “PIKFYVE inhibition increases the number of EEA1-positive endosomes and LAMP1-positive lysosomes”

    From ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids (2021) · cites this paper as Shi et al., 2018

    The section on small-molecule regulators of endosomal trafficking (page not provided) reports that PIKFYVE inhibition increased the size of EEA1-positive endosomes, not their number. The lysosomal-biogenesis section attributes restored numbers of LAMP1-positive lysosomes to forced C9ORF72 expression; our copy does not report that PIKFYVE inhibition increased their number. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • The human iPSC line WTC11 was used in isogenic GRN+/+ and GRN−/− forms.

    “Isogenic human iPSC line WTC11 (GRN+/+ and GRN−/−) were generated by Dr. Bruce R. Conklin, as previously described (61).”

    From Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS (2025) · cites this paper as [61]

    The Methods sections on iPSC reprogramming and CRISPR/Cas9 genome editing describe patient-derived iPSCs and C9ORF72-edited cells, respectively. Searches for WTC11, GRN isogenic lines, and Bruce R. Conklin found no passage in our copy identifying the claimed GRN+/+ and GRN−/− WTC11 lines or their origin. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Induced expression of different transcription factors yields other neuron types, such as motor neurons and inhibitory neurons.

    “induced expression of different transcription factors yield other types of neurons, such as motor neurons (Hester et al., 2011; Shi et al., 2018) and inhibitory neurons (Yang et al., 2017).”
  • C9orf72 assists in the formation of nascent autophagosomes, consistent with impaired autophagy observed in murine cortical neurons and human iPSC-derived neurons upon C9orf72 knockdown.

    “Together, these findings suggest that C9orf72 assists in the formation of nascent autophagosomes, consistent with the finding of impaired autophagy in murine cortical neurons [148] and human iPSC-derived neurons [154] upon C9orf72 knockdown.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [32]Webster CP, The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J 35, 1656– 1676 (2016). 27334615 PMC4969571
  2. [39]Sellier C, Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J 35, 1276– 1297 (2016). 27103069 PMC4910533

Cited by

Sorted by citations

Authors
Shi, Y., Lin, S., Staats, K. A., Li, Y., Chang, W.-H., Hung, S.-T., Hendricks, E., Linares, G. R., Wang, Y., Son, E. Y., Wen, X., Kisler, K., Wilkinson, B., Menendez, L., Sugawara, T., Woolwine, P., Huang, M., Cowan, M. J., Ge, B., Koutsodendris, N., Sandor, K. P., Komberg, J., Vangoor, V. R., Senthilkumar, K., Hennes, V., Seah, C., Nelson, A. R., Cheng, T.-Y., Lee, S.-J. J., August, P. R., Chen, J. A., Wisniewski, N., Hanson-Smith, V., Belgard, T. G., Zhang, A., Coba, M., Grunseich, C., Ward, M. E., van den Berg, L. H., Pasterkamp, R. J., Trotti, D., Zlokovic, B. V., & Ichida, J. K.
Affiliations
  • University of Southern California (US)
  • Stanford Medicine (US)
  • Thomas Jefferson University (US)
  • University Medical Center Utrecht (NL)
  • DRVision Technologies (United States) (US)
  • Verge Genomics (United States) (US)
  • National Institutes of Health (US)
Corresponding author
Ichida, Justin K
Venue
Nature Medicine
Published
2018-02-05
Volume
24
Issue
3
Pages
313-325
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2787234767
Cited by
566
References
66
Citations by year
2026: 23 · 2025: 59 · 2024: 63 · 2023: 73 · 2022: 64 · 2021: 86 · 2020: 83 · 2019: 68 · 2018: 47
FWCI
48.22
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Utrecht University Repository (Utrecht University) (submittedVersion)
Funders
  • National Institute on Aging (R01AG023084, R01AG039452, R37AG023084, P50AG005142, RF1AG039452, P01AG052350)
  • National Institute on Deafness and Other Communication Disorders (R01DC015530, T32DC009975)
  • National Institute of Neurological Disorders and Stroke (R21NS090912, R00NS077435, R37NS034467, R01NS097850, K99NS077435, R01NS034467)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
C9orf72, GGGGCC repeat expansion, amyotrophic lateral sclerosis, frontotemporal dementia, haploinsufficiency, motor neurons, neurodegeneration, vesicle trafficking, lysosomal biogenesis, endosomes, glutamate receptors, excitotoxicity, dipeptide repeat proteins, Rab5, ALS2, FIG4, CHMP2B, optineurin, p62
MeSH terms
C9orf72 Protein, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Gene Expression Regulation, Humans, Introns, Motor Neurons, Mutation, Nerve Degeneration, Endosomes, rab5 GTP-Binding Proteins, DNA Repeat Expansion, Frontotemporal Dementia, Haploinsufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review